Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Open-label, Parallel-group, Comparative Study to Evaluate the Effects of Renal or Hepatic Impairment on TAK-272 Pharmacokinetics With a Single Oral Administration of TAK-272 in Patients With Renal or Hepatic Impairment

NCT02367872 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02367872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02367872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Open-label, Parallel-group, Comparative Study to Evaluate the Effects of Renal or Hepatic Impairment on TAK-272 Pharmacokinetics With a Single Oral Administration of TAK-272 in Patients With Renal or Hepatic Impairment
Lead sponsor
Takeda
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2015
Completion date
June 30, 2016
Enrollment
48 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment, renal impairment